Events Partner Content 6th Microbiome Movement - Drug Development Summit Discover the Next Generation of Microbiome Therapeutics
News Dizal set to bring lung cancer drug Zegfrovy to US Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
